These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 33865627)

  • 21. Overwhelming Postsplenectomy Infection: A Prospective Multicenter Cohort Study.
    Theilacker C; Ludewig K; Serr A; Schimpf J; Held J; Bögelein M; Bahr V; Rusch S; Pohl A; Kogelmann K; Frieseke S; Bogdanski R; Brunkhorst FM; Kern WV
    Clin Infect Dis; 2016 Apr; 62(7):871-878. PubMed ID: 26703862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pneumococcal vaccination coverage in individuals (16-59 years) with a newly diagnosed risk condition in Germany.
    Deb A; Podmore B; Barnett R; Beier D; Galetzka W; Qizilbash N; Haeckl D; Boellinger T; Johnson KD; Weiss T
    BMC Infect Dis; 2022 Sep; 22(1):753. PubMed ID: 36171549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serotype Changes and Drug Resistance in Invasive Pneumococcal Diseases in Adults after Vaccinations in Children, Japan, 2010-2013.
    Ubukata K; Chiba N; Hanada S; Morozumi M; Wajima T; Shouji M; Iwata S;
    Emerg Infect Dis; 2015 Nov; 21(11):1956-65. PubMed ID: 26485679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pneumococcal and influenza immunization in asplenic persons: a retrospective population-based cohort study 1990-2002.
    Langley JM; Dodds L; Fell D; Langley GR
    BMC Infect Dis; 2010 Jul; 10():219. PubMed ID: 20649965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adverse Reactions to Pneumococcal Vaccine in Pediatric and Adolescent Patients with Sickle Cell Disease.
    Han J; Kemiki O; Hsu LL; Rivers AE
    Pharmacotherapy; 2015 Jul; 35(7):696-700. PubMed ID: 26095207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of 23-valent pneumococcal polysaccharide vaccine on elderly long-term cancer survivors: a population-based propensity score matched cohort study.
    Chiou WY; Lee MS; Hung SK; Lin HY; Lo YC; Hsu FC; Tsai SJ; Li CY
    BMJ Open; 2018 May; 8(5):e019364. PubMed ID: 29769253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).
    ;
    MMWR Morb Mortal Wkly Rep; 2010 Sep; 59(34):1102-6. PubMed ID: 20814406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
    De Montalembert M; Abboud MR; Fiquet A; Inati A; Lebensburger JD; Kaddah N; Mokhtar G; Piga A; Halasa N; Inusa B; Rees DC; Heath PT; Telfer P; Driscoll C; Al Hajjar S; Tozzi A; Jiang Q; Emini EA; Gruber WC; Gurtman A; Scott DA
    Pediatr Blood Cancer; 2015 Aug; 62(8):1427-36. PubMed ID: 25810327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distribution and annual changes in the proportion of Streptococcus pneumoniae serotypes in Japanese adults with pneumococcal pneumonia from 2011 to 2017.
    Noguchi S; Yatera K; Akata K; Chang B; Ikegami H; Hata R; Yamasaki K; Kawanami T; Mukae H
    J Infect Chemother; 2019 Nov; 25(11):925-929. PubMed ID: 31350184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination status and immune response to 13-valent pneumococcal conjugate vaccine in asplenic individuals.
    Nived P; Jørgensen CS; Settergren B
    Vaccine; 2015 Mar; 33(14):1688-94. PubMed ID: 25707692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia.
    Vila-Corcoles A; Ochoa-Gondar O; Hospital I; de Diego C; Satué E; Bladé J; Ansa X; Guzmán JA; Salsench E; Ramos F
    Hum Vaccin Immunother; 2016 Nov; 12(11):2953-2958. PubMed ID: 27454779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of pneumococcal vaccination with cardiovascular diseases in older adults: The vaccine effectiveness, networking, and universal safety (VENUS) study.
    Narii N; Kitamura T; Komukai S; Zha L; Komatsu M; Murata F; Maeda M; Kiyohara K; Sobue T; Fukuda H
    Vaccine; 2023 Mar; 41(13):2307-2313. PubMed ID: 36870877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune thrombocytopenic purpura and Guillain-Barré syndrome after 23-valent pneumococcal polysaccharide vaccination in Japan: The vaccine effectiveness, networking, and universal safety (VENUS) study.
    Sato S; Katsuta T; Kawazoe Y; Takahashi M; Murata F; Maeda M; Fukuda H; Kamidani S
    Vaccine; 2024 Jan; 42(1):4-7. PubMed ID: 38044244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody persistence 5 years after a 13-valent pneumococcal conjugate vaccine in asplenic patients with β-thalassemia: assessing the need for booster.
    Papadatou I; Lagousi T; Kattamis A; Spoulou V
    Ann Hematol; 2019 Mar; 98(3):775-779. PubMed ID: 30683996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China.
    Zhao D; Gai Tobe R; Cui M; He J; Wu B
    Vaccine; 2016 Dec; 34(50):6158-6165. PubMed ID: 27838068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label study.
    Cordonnier C; Ljungman P; Juergens C; Maertens J; Selleslag D; Sundaraiyer V; Giardina PC; Clarke K; Gruber WC; Scott DA; Schmoele-Thoma B;
    Clin Infect Dis; 2015 Aug; 61(3):313-23. PubMed ID: 25870329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antigen-specific B-cell response to 13-valent pneumococcal conjugate vaccine in asplenic individuals with β-thalassemia previously immunized with 23-valent pneumococcal polysaccharide vaccine.
    Papadatou I; Piperi C; Alexandraki K; Kattamis A; Theodoridou M; Spoulou V
    Clin Infect Dis; 2014 Sep; 59(6):862-5. PubMed ID: 24879786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.